These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17519080)

  • 1. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    He YL; Sabo R; Riviere GJ; Sunkara G; Leon S; Ligueros-Saylan M; Rosenberg M; Dole WP; Howard D
    Curr Med Res Opin; 2007 May; 23(5):1131-8. PubMed ID: 17519080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
    He YL; Sabo R; Picard F; Wang Y; Herron J; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
    He YL; Sabo R; Campestrini J; Wang Y; Ligueros-Saylan M; Lasseter KC; Dilzer SC; Howard D; Dole WP
    Eur J Clin Pharmacol; 2007 Jul; 63(7):677-86. PubMed ID: 17486328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
    Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
    Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
    Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
    J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
    He YL; Ito H; Yamaguchi M; Terao S; Shimada S; Irie S; Sekiguchi K
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
    Ayalasomayajula SP; Dole K; He YL; Ligueros-Saylan M; Wang Y; Campestrini J; Humbert H; Sunkara G
    Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.
    He YL; Paladini S; Sabia H; Campestrini J; Zhang Y; Leon S; Ligueros-Saylan M; Jarugula V
    Int J Clin Pharmacol Ther; 2008 May; 46(5):259-67. PubMed ID: 18538112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
    He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
    Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
    He YL; Flannery B; Campestrini J; Leon S; Zinny MA; Ligueros-Saylan M; Jarugula V
    Curr Med Res Opin; 2008 Jun; 24(6):1703-9. PubMed ID: 18471347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.
    He YL; Sabo R; Sunkara G; Bizot MN; Riviere GJ; Leon S; Ligueros-Saylan M; Dole WP; Howard D
    J Clin Pharmacol; 2007 Aug; 47(8):998-1004. PubMed ID: 17660482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
    He YL; Yamaguchi M; Ito H; Terao S; Sekiguchi K
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):582-95. PubMed ID: 20860912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.
    Hu P; Yin Q; Deckert F; Jiang J; Liu D; Kjems L; Dole WP; He YL
    J Clin Pharmacol; 2009 Jan; 49(1):39-49. PubMed ID: 18832295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
    He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
    Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
    Wang X; Zhang D; Xu W; Liu H; Wang W
    Xenobiotica; 2010 Oct; 40(10):707-12. PubMed ID: 20735236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.